Table 3.

Comparison between EBM on LPS and Survey results.

P-LPS	EBM	Survey results % (n)
Initiation of administration	OR0–OR+3	OR0 71 % (105/148) OR+1 23.6% (35/148) OR+2 3.38% (5/148) OR+3 2.02% (3/148)
Routes and dosages	Vaginal Micronized P IM P 50 mg/d Subcutaneous P 25 mg/d OS Dydrogesterone 30 mg/d	600 mg/d or 200/400 mg/d 80% (119/148) 50–100 mg/d 6% (9/148) 25 mg/d 5% (7/148) 20/30 mg/d 5% (7/148) Combined regimen: Vag + OS/IM 4% (6/148)
Discontinuation of administration	At least until the pregnancy test	PT 6% (9/148) US 7% (10/148) 7/8 weeks 22% (33/148) 10 weeks 13% (19/148) 12 weeks 52% (77/148)

Number of respondent doctors are expressed as percentage (%) and number (n).

P: Progesterone; LPS: luteal phase support; EBM: evidence-based medicine; OR0: oocytes retrieval evening; OR+1: one day after oocytes retrieval; OR+2: two days after oocytes retrieval; OR+3: three days after oocytes retrieval; IM: intramuscular; OS: oral; Vag: vaginal, mg/d: mg per day, PT: pregnancy test; US: ultrasound with detection of hearth activity. EBM data are based on the latest ESHRE guideline on ovarian stimulation: “Group EREG.OVARIAN STIMULATION FOR IVF/ICSI. Guideline of the European Society of Human Reproduction and Emnbriology.2019”.